Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center

Articles

Bone Marrow Transplant for Patients With MF

July 20th 2021

Expert panelists review important disease-related and patient-related factors when considering bone marrow transplant in patients with primary myelofibrosis.

Fedratinib for Patients With Primary Myelofibrosis

July 13th 2021

Pankit Vachhani, MD, guides a discussion on the FDA approval of fedratinib and reviews how it has affected the therapeutic landscape for patients with primary myelofibrosis.

Ruxolitinib for Patients With Primary Myelofibrosis

July 13th 2021

MPN expert Srdan Verstovsek, MD, PhD, shares insights into the role of ruxolitinib for the treatment of myelofibrosis.

Monitoring Disease Response or Progression in MF

July 6th 2021

An expert in the management of myeloproliferative neoplasms, Jamile Shammo, MD, FASCP, FACP, leads a discussion on best practices for assessing response and monitoring for progression.

Recent Updates to NCCN Guidelines on MF Treatment

July 6th 2021

Pankit Vachhani, MD, reviews recent changes to the NCCN Guidelines, highlighting the addition of luspatercept for the treatment of primary myelofibrosis.

Therapeutic Decision-Making for Primary Myelofibrosis

June 29th 2021

Key opinion leaders in the management of myeloproliferative neoplasms review factors to consider when selecting treatments for patients and highlight the role of fedratinib in the first- or second-line settings.

Diagnosis and Prognosis of Primary Myelofibrosis

June 29th 2021

A panel of experts in myeloid malignancies begins with a discussion on risk assessment criteria, next-generation sequencing, and symptom burden questionnaires to assess prognosis for patients with myelofibrosis.

Unmet Needs and Looking Ahead in Essential Thrombocythemia

April 21st 2021

Unmet needs and current areas that are being studied in in essential thrombocythemia.

The Treatment Spectrum in Essential Thrombocythemia

April 21st 2021

Pankit Vachhani, MD, highlights treatment considerations in low- to high-risk essential thrombocythemia and patients resistant or intolerant to hydroxyurea.

Essential Thrombocythemia: An Overview

April 14th 2021

Expert discusses risk-stratification models, prognosis, and the management of complications in essential thrombocythemia.

Ongoing Unmet Needs and New Approaches in Myelofibrosis

April 14th 2021

Key opinion leaders discuss the current unmet needs in myelofibrosis and ongoing approaches to look forward to in hopefully overcoming these challenges.

A Review of Pacritinib and PACIFICA Data

April 7th 2021

Srdan Verstovsek, MD, PhD, briefly reviews the role of pacritinib in patients with myelofibrosis as well as the PACIFICA study.

The Role of Transplant in Myelofibrosis

April 7th 2021

Experts discuss the role of transplant and evaluating options in patients with myelofibrosis.

COMFORT Data and Ruxolitinib in Myelofibrosis

March 31st 2021

A review of data from the COMFORT trials and the management and real-world use of ruxolitinib in patients with myelofibrosis, also touching on its use during the coronavirus pandemic.

A Look at Fedratinib and the JAKARTA Trials

March 31st 2021

Srdan Verstovsek, MD, PhD, reviews data from the JAKARTA and JAKARTA2 clinical trials as well as his approach to using fedratinib in his own clinical practice.

Risk, Prognosis, and Nontransplant Options in Primary Myelofibrosis

March 24th 2021

Ruben A. Mesa, MD, and Srdan Verstovsek, MD, PhD, provide insight on the disease burden and prognostic scoring of primary myelofibrosis, as well as options for nontransplant candidates.

Goals in Treating Low-Risk Primary Myelofibrosis

March 24th 2021

Srdan Verstovsek, MD, PhD, shares how he assesses and typically starts treatment in patients with low-risk primary myelofibrosis, looking specifically at whether patients are symptomatic or asymptomatic.

Emerging Therapeutic Options in Polycythemia Vera

March 17th 2021

What to look forward to in the polycythemia vera space, including new clinical trials.

Real-World Use of Ruxolitinib in Polycythemia Vera

March 17th 2021

Experts give real-world insight in using ruxolitinib in patients with polycythemia vera.

Polycythemia Vera: An Update on Clinical Trials

March 10th 2021

Experts discuss clinical trial updates in polycythemia vera, including data from RESPONSE, RESPONSE-2, an international observational study of ruxolitinib, and REVEAL.